Search
for
Sort by
Research 30 of 1000+
- Association of 5-α reductase inhibitors and sexual dysfunction: A RADAR report
- Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System
- Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases
- Drug-associated insomnia: A pharmacovigilance study based on FDA adverse event reporting system
- Suicidality Risks Associated with Finasteride, a 5-Alpha Reductase Inhibitor: An Evaluation of Real-World Data from the FDA Adverse Event Reports
- Ovary and uterus related adverse events associated with statin use: an analysis of the FDA Adverse Event Reporting System
- Assessing the safety of topical minoxidil through disproportionality analysis of FAERS reports
- Drug-associated gingival disorders: a retrospective pharmacovigilance assessment using disproportionality analysis
- PŁYNY- NIE ZA DUŻO, NIE ZA MAŁO, LECZ W SAM RAZ
- Neuropsychiatric Adverse Events of Montelukast: An Analysis of Real-World Datasets and drug−gene Interaction Network
- Digoxin-induced anemia among patients with atrial fibrillation and heart failure: clinical data analysis and drug-gene interaction network
- Recent advances in electrospun nanofibers for wound healing
- THE USE OF AN IMMUNOMODULATOR WITH AN ANTISEPTIC IN THE TREATMENT OF INFECTED AND PURULENT WOUNDS IN AN EXPERIMENT
- Verrucous hemangioma leg: A challenging birthmark
- Successful treatment of ulcerated infantile hemangioma associated with PELVIS syndrome using oral propanolol
- POSTĘP W DIAGNOZIE I LECZENIU STWARDNIENIA ROZSIANEGO
- Male Breast Cancer and 5α-Reductase Inhibitors Finasteride and Dutasteride
- The Novel Excipient, Dodecyl-2-N, N-dimethylaminopropionate Hydrochloride (DDAIP-HCl) Improves the Flux of Minoxidil in Human Skin
- Case Report: Vitiligo and Alopecia Universalis Following Rituximab Therapy in a Patient with Myasthenia Gravis
- Teriflunomide efficacy, safety and tolerability in patients with relapsing forms of multiple sclerosis
- Agglomerative clustering-based drugs graded for the risk signals of drug-induced cognitive disorder: a study on the FAERS database
- A cross‐sectional analysis of medications used by patients reporting alopecia areata on the FDA adverse events reporting system
- Shedding light on the FDA’s 510(k) approvals process: low-level laser therapy devices used in the treatment of androgenetic alopecia
- FDA Reports of Alopecia as an Adverse Event to Isotretinoin
- FDA approves Pfizer's JAK inhibitor for adolescents with alopecia areata hair loss
- FDA approval of Deuruxolitinib: A New Treatment Option for Severe Alopecia Areata
- Are finasteride-related penile curvature/Peyronie’s disease Adverse Event Reports worthy of further clinical investigation? Disproportionality analysis based on both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases
- FDA declines approval of testosterone drug for third time
- Drug-induced erectile dysfunction: a real-world pharmacovigilance study using the FDA adverse event reporting system database
- FDA Approved pediatric antihypertensive agents